Mucosal permeability after subclinical intestinal ischemia-reperfusion injury: an exploration of possible mechanisms.
Changes in mucosal permeability may be important in the etiology of necrotizing enterocolitis. The authors have previously shown that subclinical ischemia-reperfusion injury results in increased permeability in the rat intestine, and have partially characterized this phenomenon. In the present study the authors attempt to determine the mechanism by which these changes occur. Six-week-old rats underwent 10-minute superior mesenteric artery occlusion (SMAO) or sham, and mucosal permeability to 51CrEDTA was measured after 30 minutes. Rats were pretreated with saline, inhibitors of oxygen free radicals (superoxide dismutase+catalase, vitamin E, allopurinol, alpha-phenyl-N-tert butyl-nitrone), inhibitors of eicosanoids (indomethacin, quinacrine, diethylcarbamazine, 13-azaprostanoic acid), the putative cytoprotective agent prostaglandin E2, or the inhibitor of neutrophil free radical production fructose 1-6 diphosphate. None of the agents significantly attenuated the increase in mucosal permeability caused by SMAO, although indomethacin and prostaglandin E2 significantly exacerbated the permeability changes. To further explore the role of neutrophils, tissue myeloperoxidase was measured 30 minutes after SMAO. There was no significant difference in myeloperoxidase levels between sham and SMAO animals. These data suggest that the early increase in mucosal permeability after subclinical ischemia-reperfusion injury is not mediated by oxygen free radicals, eicosanoids, or neutrophils. The deleterious effect of indomethacin and prostaglandin E2 suggests a possible protective role for the cyclooxygenase system, but further studies are necessary to elucidate this possibility.
Langer
J C
JC
Intestinal Disease Research Unit, McMaster University, Hamilton, Ontario.
Sohal
S S
SS
Blennerhassett
P
P
D000818:Animals; D002860:Chromium Radioisotopes; D015232:Dinoprostone / Q000494:pharmacology; D004492:Edetic Acid; D015777:Eicosanoids / Q000037:antagonists & inhibitors; D004761:Enterocolitis, Pseudomembranous / Q000209:etiology; D005609:Free Radicals / Q000037:antagonists & inhibitors; D005635:Fructosediphosphates / Q000494:pharmacology; D007155:Immunologic Factors / Q000494:pharmacology; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000502:physiology*; D007422:Intestines / Q000098:blood supply*; D008297:Male; D009504:Neutrophils / Q000502:physiology; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000503:physiopathology* / Q000517:prevention & control; D014886:Weaning
D002860:Chromium Radioisotopes; D015777:Eicosanoids; D005609:Free Radicals; D005635:Fructosediphosphates; D007155:Immunologic Factors; D004492:Edetic Acid; D009195:Peroxidase; D015232:Dinoprostone; C029063:fructose-1,6-diphosphate